A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

Recruiting now · Phase 1

Conditions studied: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor

In brief

This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.

Key facts

Study ID

NCT06952010

Run by

Exelixis

People needed

303

Starts

2025-05-01

Expected to finish

2027-11-30

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Exelixis Clinical Site #5 — San Francisco, California, United States (enrolling)
• Exelixis Clinical Site #4 — New Haven, Connecticut, United States (enrolling)
• Exelixis Clinical Site #8 — Tampa, Florida, United States (enrolling)
• Exelixis Clinical Site #10 — Boston, Massachusetts, United States (enrolling)
• Exelixis Clinical Site #11 — Boston, Massachusetts, United States (enrolling)
• Exelixis Clinical Site #6 — St Louis, Missouri, United States (enrolling)
• Exelixis Clinical Site #7 — New York, New York, United States (enrolling)
• Exelixis Clinical Site #1 — Hickory, North Carolina, United States (enrolling)
• Exelixis Clinical Site #3 — Nashville, Tennessee, United States (enrolling)
• Exelixis Clinical Site #9 — Houston, Texas, United States (enrolling)
• Exelixis Clinical Site #2 — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.